OJTS  Vol.4 No.3 , September 2014
Implications of the VerifyNow P2Y12 Assay on Patient Outcomes
ABSTRACT
Background: The platelet inhibitory response of clopidogrel is substantially variable among patients, and numerous studies have shown that post-percutaneous intervention, patients with high on-treatment platelet reactivity have an increase in risk of major adverse cardiovascular events. No published studies to date have utilized platelet function monitoring assays prior to coronary artery bypass graft (CABG) surgery, but determination of patients’ antiplatelet effects prior to surgery may decrease time to surgery and length of hospital stay. The purpose of the study was to evaluate the clinical outcomes of non-elective CABG patients analyzed by the VerifyNow P2Y12 platelet-function monitoring assay prior to surgery compared to a similar set of patients not analyzed by the VerifyNow P2Y12 assay. Methods: This was a retrospective, single center, cohort study. The primary endpoints of this study were time to surgery and length of hospital stay. Results: From March 2013 to July 2013, 60 patient charts were reviewed and included in this study. 49 patients were analyzed by the VerfiyNow P2Y12 assay, and 16 of these patients underwent non-elective CABG surgery. Eleven patients underwent non-elective CABG surgery and were not analyzed by the VerifyNow P2Y12 assay. There was no difference between groups regarding time to surgery (p = 0.75) or length of stay (p = 0.42). Based on the assay’s P2Y12 reaction unit results, 69% of VerifyNow P2Y12 patients went to surgery sooner than the institution’s recommendations which generated more bleeding events, half of which were considered major bleeds. Conclusions: Utilization of the VerifyNow P2Y12 assay prior to non-elective CABG surgery does not shorten time to surgery or overall length of hospital stay. However, insufficient P2Y12 reaction units prior to surgery may lead to more bleeding events, thus the application of platelet function monitoring assays prior to procedures may be beneficial as a bleeding risk-assessment tool.

Cite this paper
Sutter, D. , King, G. and Short, M. (2014) Implications of the VerifyNow P2Y12 Assay on Patient Outcomes. Open Journal of Thoracic Surgery, 4, 78-85. doi: 10.4236/ojts.2014.43016.
References
[1]   Levine, G.N., Bates, E.R., Blankenship, J.C., Bailey, S.R., Bittl, J.A., Cercek, B., Chambers, C.E., Ellis, S.G., Guyton, R.A., Hollenberg, S.M., Khot, U.N., Lange, R.A., Mauri, L., Mehran, R., Moussa, I.D., Mukherjee, D., Nallamothu, B.K. and Ting, H.H. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 124, e574-e651.
http://dx.doi.org/10.1161/CIR.0b013e31823ba622

[2]   Hillis, L.D., Smith, P.K., Anderson, J.L., Bittl, J.A., Bridges, C.R., Byrne, J.G., Cigarroa, J.E., Disesa, V.J., Hiratzka, L.F., Hutter Jr., A.M., Jessen, M.E., Keeley, E.C., Lahey, S.J., Lange, R.A., London, M.J., Mack, M.J., Patel, M.R., Puskas, J.D., Sabik, J.F., Selnes, O., Shahian, D.M., Trost, J.C. and Winniford, M.D. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 124, e652-e735.
http://dx.doi.org/10.1161/CIR.0b013e31823c074e

[3]   Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E., Alfonso, F., Macaya, C., Bass, T.A. and Costa, M.A. (2007) Variability in Individual Responsiveness to Clopidogrel: Clinical Implications, Management, and Future Perspectives. Journal of the American College of Cardiology, 49, 1505-1516.
http://dx.doi.org/10.1016/j.jacc.2006.11.044

[4]   Gurbel, P.A., Bliden, K.P., Hiatt, B.L. and O’Connor, C.M. (2003) Clopidogrel for Coronary Stenting: Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity. Circulation, 107, 2908-2913.
http://dx.doi.org/10.1161/01.CIR.0000072771.11429.83

[5]   Price, M.J., Coleman, J.L., Steinhubl, S.R., Wong, G.B., Cannon, C.P. and Teirstein, P.S. (2006) Onset and Offset of Platelet Inhibition after High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers. American Journal of Cardiology, 98, 681-684.
http://dx.doi.org/10.1016/j.amjcard.2006.03.054

[6]   Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L. and Topol, E.J. (2005) Variability in Platelet Responsiveness to Clopidogrel among 544 Individuals. Journal of the American College of Cardiology, 45, 246-251.
http://dx.doi.org/10.1016/j.jacc.2004.09.067

[7]   Geisler, T., Langer, H., Wydymus, M., Gohring, K., Zurn, C., Bigalke, B., Stellos, K., May, A.E. and Gawaz, M. (2006) Low Response to Clopidogrel Is Associated with Cardiovascular Outcome after Coronary Stent Implantation. European Heart Journal, 27, 2420-2425.
http://dx.doi.org/10.1093/eurheartj/ehl275

[8]   Marcucci, R., Gori, A.M., Paniccia, R., Giusti, B., Valente, S., Giglioli, C., Buonamici, P., Antoniucci, D., Abbate, R. and Gensini, G.F. (2009) Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up. Circulation, 119, 237-242.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.812636

[9]   Price, M.J., Endemann, S., Gollapudi, R.R., Valencia, R., Stinis, C.T., Levisay, J.P., Ernst, A., Sawhney, N.S., Schatz, R.A. and Teirstein, P.S. (2008) Prognostic Significance of Post-Clopidogrel Platelet Reactivity Assessed by a Point-of-Care Assay on Thrombotic Events after Drug-Eluting Stent Implantation. European Heart Journal, 29, 992-1000.
http://dx.doi.org/10.1093/eurheartj/ehn046

[10]   Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A., Kastrati, A. and von Beckerath, N. (2009) Platelet Reactivity after Clopidogrel Treatment Assessed with Point-of-Care Analysis and Early Drug-Eluting Stent Thrombosis. Journal of the American College of Cardiology, 53, 849-856.
http://dx.doi.org/10.1016/j.jacc.2008.11.030

[11]   Yamaguchi, Y., Abe, T., Sato, Y., Matsubara, Y., Moriki, T. and Murata, M. (2013) Effects of VerifyNow P2Y12 Test and CYP2C19*2 Testing on Clinical Outcomes of Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis. Platelets, 24, 352-361.
http://dx.doi.org/10.3109/09537104.2012.700969

[12]   Sambu, N. and Curzen, N. (2011) Monitoring the Effectiveness of Antiplatelet Therapy: Opportunities and Limitations. British Journal of Clinical Pharmacology, 72, 683-696.
http://dx.doi.org/10.1111/j.1365-2125.2011.03955.x

[13]   van Werkum, J.W., Harmsze, A.M., Elsenberg, E.H., Bouman, H.J., ten Berg, J.M. and Hackeng, C.M. (2008) The Use of the VerifyNow System to Monitor Antiplatelet Therapy: A Review of the Current Evidence. Platelets, 19, 479-488.
http://dx.doi.org/10.1080/09537100802317918

[14]   VerifyNow P2Y12 Platelet Reactivity Test [Package Insert]. Accumetrics, San Diego, CA, 2013.

[15]   Jakubowski, J.A., Payne, C.D., Li, Y.G., Brandt, J.T., Small, D.S., Farid, N.A., Salazar, D.E. and Winters, K.J. (2008) The Use of the VerifyNow P2Y12 Point-of-Care Device to Monitor Platelet Function across a Range of P2Y12 Inhibition Levels Following Prasugrel and Clopidogrel Administration. Thrombosis and Haemostasis, 99, 409-415.

[16]   Paniccia, R., Antonucci, E., Gori, A.M., Marcucci, R., Giglioli, C., Antoniucci, D., Gensini, G.F., Abbate, R. and Prisco, D. (2007) Different Methodologies for Evaluating the Effect of Clopidogrel on Platelet Function in High-Risk Coronary Artery Disease Patients. Journal of Thrombosis and Haemostasis, 5, 1839-1847.
http://dx.doi.org/10.1111/j.1538-7836.2007.02656.x

[17]   Van Werkum, J.W., van der Stelt, C.A., Seesing, T.H., Hackeng, C.M. and ten Berg, J.M. (2006) A Head-to-Head Comparison between the VerifyNow P2Y12 Assay and Light Transmittance Aggregometry for Monitoring the Individual Platelet Response to Clopidogrel in Patients Undergoing Elective Percutaneous Coronary Intervention. Journal of Thrombosis and Haemostasis, 4, 2516-2518.
http://dx.doi.org/10.1111/j.1538-7836.2006.02187.x

[18]   von Beckerath, N., Pogatsa-Murray, G., Wieczorek, A., Sibbing, D., Schomig, A. and Kastrati, A. (2006) Correlation of a New Point-of-Care Test with Conventional Optical Aggregometry for the Assessment of Clopidogrel Responsiveness. Thrombosis and Haemostasis, 95, 910-911.

[19]   Price, M.F., Endermann, S., Gallopudi, R.R., Valencia, R., Stinis, C.T., Levisay, J.P., Ernst, A., Sawhney, N.S., Schatz, R.A. and Teirstein, P.S. (2008) Prognostic Significance of Post-Clopidogrel Platelet Reactivity Assessed by a Point-of-Care Assay on Thrombotic Events after Drug-Eluting Stent Implantation. European Heart Journal, 29, 992-1000.
http://dx.doi.org/10.1093/eurheartj/ehn046

[20]   Patti, G., Nusca, A., Mangiacapra, F., Gatto, L., D’Ambrosio, A. and Di Sciascio, G. (2008) Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention Results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) Study. Journal of the American College of Cardiology, 52, 1128-1133.
http://dx.doi.org/10.1016/j.jacc.2008.06.038

[21]   Marcucci, R., Gori, A.M., Paniccia, R., Giusti, B., Valente, S., Giglioli, C., Buonamici, P., Antoniucci, D., Abbate, R. and Gensini, G.F. (2009) Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicated by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay. Circulation, 119, 237-242.
http://dx.doi.org/10.1161/CIRCULATIONAHA.108.812636

[22]   Breet, N.J., van Werkum, J.W., Bouman, H.J., Kelder, J.C., Ruven, H.J., Bal, E.T., Deneer, V.H., Harmsze, A.M., van der Heyden, J.A., Rensing, B.J., Suttorp, M.J., Hackeng, C.M. and ten Berg, J.M. (2010) Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA, 303, 754-762.
http://dx.doi.org/10.1001/jama.2010.181

[23]   Price, M.J., Berger, P.B., Teirstein, P.S., Tanguay, J.F., Angiolillo, D.J., Spriggs, D., Puri, S., Robbins, M., Garratt, K.R., Bertrand, O.F., Stillabower, M.E., Aragon, J.R., Kandzari, D.E., Stinis, C.T., Lee, M.S., Manoukian, S.V., Cannon, C.P., Schork, M.J. and Topol, E.J. (2011) Sandard-vs High-Dose Clopidogrel Based on Platelet Function Testing after Percutaneous Coronary Intervention: The GRAVITAS Randomized Trial. JAMA, 305, 1097-1105.
http://dx.doi.org/10.1001/jama.2011.290

[24]   Kahn, S.R., Lim, W., Dunn, A.S., Cushman, M., Dentali, F., Akl, E.A., Cook, D.J., Balekian, A.A., Klein, R.C., Le, H., Schulman, S. and Murad, M.H. (2012) Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e195S-e226S.

 
 
Top